We are live on ! Find out more

Tonix Pharmaceuticals

TNXP

Market cap $92.4M

5.39 USD

+0.09

1.7%

At close Updated Oct 27, 4:00 PM EDT

Pre-market

After hours

5.40

+0.01

0.19%

1 day

1.7%

5 days

-7.86%

1 month

-45.56%

3 months

-48.02%

6 months

-58.02%

Year to date

-67.43%

1 year

-73.51%

5 years

-100%

10 years

-100%

About: Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Employees: 142

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 21.4%

Neutral 78.6%

Negative 0%

Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain

TONMYA improved Fibromyalgia Impact Questionnaire-Revised (FIQR) symptoms and function scores versus placebo in both domains at Week 14 in RELIEF and RESILIENT Phase 3 pivotal studies Tonix commercially launched TONMYA® in November 2025, the first fibromyalgia drug for adults in the U.S. in over 15 years approved by the U.S. Food and Drug Administration (FDA) BERKELEY HEIGHTS, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, presented data from an analysis of the Phase 3 RELIEF and RESILIENT studies of TONMYA® (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults demonstrating outcomes as measured by the Fibromyalgia Impact Questionnaire-Revised (FIQR) at the International Association for the Study of Pain (IASP) 2026 World Congress on Pain, held October 26-30, 2026, in Bangkok, Thailand.

Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain

Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026

BERKELEY HEIGHTS, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biotechnology company, today announced that it will host a conference call and webcast to report third quarter 2026 financial results and operational highlights on Monday, November 9, 2026, at 8:30 a.m.

Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026

Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain

BERKELEY HEIGHTS, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced a poster examining the effects of TONMYA® (cyclobenzaprine HCl sublingual tablets) on fibromyalgia symptoms and physical function will be presented at the International Association for the Study of Pain (IASP) 2026 World Congress on Pain, held October 26-30, 2026, in Bangkok, Thailand.

Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026

BERKELEY HEIGHTS, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced an oral presentation on TNX-801, a live, attenuated, minimally replicative investigational vaccine platform based on horsepox virus to protect against mpox and other infectious diseases, and a working group session led by Tonix, “Vectored Vaccine Platforms: From Design to Improving Efficacy,” at the World Vaccine Congress Europe held in Amsterdam, Netherlands on October 19-21, 2026.

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

New agreement, effective immediately, adds approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.) Commercial and government payer coverage for TONMYA now reaches approximately 166 million covered lives (53% of total U.S. lives) BERKELEY HEIGHTS, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced a second major managed Medicare agreement for TONMYA® (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults that is effective immediately, adding approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.).

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears

Tonix Pharmaceuticals NASDAQ: TNXP CEO Seth Lederman told attendees at the Cantor Healthcare Conference that the company's near-term focus is the commercial launch of TONMYA, its FDA-approved treatment for fibromyalgia in adults, while it advances development programs in Lyme disease prevention and transplant rejection.

Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

BERKELEY HEIGHTS, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced the promotion of Thomas Englese to Chief Commercial Officer, effective immediately.

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference

BERKELEY HEIGHTS, N.J., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced that the management team will participate in a fireside chat and 1x1s at Cantor's 2026 Global Healthcare Conference, being held September 9-11, 2026, in New York.

Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference

Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline

Tonix Pharmaceuticals NASDAQ: TNXP is focusing its near-term strategy on the commercial launch of TONMYA for fibromyalgia while advancing development programs in Lyme disease prevention and major depressive disorder, Chief Executive Officer Seth Lederman said during a Canaccord Genuity conference presentation.

Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline

Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript

Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript

Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript

See News Rankings

Price charts implemented using Lightweight Charts™